Pilatus Biosciences, a preclinical-stage biopharmaceutical company spun out from the Ludwig Institute for Cancer Research (Lausanne) in November 2022, stands on the cutting-edge of developing First-in-Class Biologics. Our pioneering approach, backed by the Cancer Research Institute (New York), we employ a pioneering approach to immunometabolism, reprogramming the immune tumor microenvironment (TME) to combat cancer effectively. The lead molecule PLT012, a humanized anti-CD36 antibody, with a unique Dual MOA – simultaneously disarming Immunosuppress cell populations and amplifying Effectors cell functions, has showcased potentials on multiple tumors with unmet medical needs and planned its first US IND submission and First Patient Dosing in 2025. PLT012 demonstrates remarkable anti-tumor efficacy in Colorectal Cancer and Liver Cancer, earning strong endorsement from professionals worldwide and receiving Orphan Drug Designation (ODD) from the FDA.